Key Points
- EVP Anat Hakim sold 5,000 Eli Lilly shares for about $7.01 million, reducing her holdings by 54.72%; the sale was made under a pre-arranged Rule 10b5-1 plan.
- Lilly’s latest quarter beat analyst estimates, with EPS of $7.48 and revenue of $24.4 billion, up 38.6% year over year. The article also reports the company raised its 2026 revenue outlook to $91 billion–$92 billion.
- Analysts largely remain positive: Lilly has a “Moderate Buy” consensus rating, with several firms recently raising their price targets.
Eli Lilly and Company (NYSE:LLY - Get Free Report) EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Anat Hakim also recently made the following trade(s):
- On Friday, August 7th, Anat Hakim sold 5,000 shares of Eli Lilly and Company stock. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00.
Eli Lilly and Company Stock Performance
Shares of NYSE LLY opened at $1,408.68 on Wednesday. The company has a market cap of $1.33 trillion, a PE ratio of 45.72, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,449.68. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The company has a 50-day simple moving average of $1,204.03 and a 200-day simple moving average of $1,095.92.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company's quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $7.02 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post 35.61 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's payout ratio is 22.46%.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. Morgan Stanley increased their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. UBS Group upped their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research note on Friday. Bank of America reiterated a "buy" rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday. Finally, Truist Financial reissued a "buy" rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $1,404.14.
Check Out Our Latest Report on Eli Lilly and Company
Trending Headlines about Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
- Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
- Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
- Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
- Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
- Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind
Hedge Funds Weigh In On Eli Lilly and Company
Several institutional investors and hedge funds have recently bought and sold shares of LLY. Marshall & Sterling Wealth Advisors Inc. raised its position in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock worth $37,000 after buying an additional 15 shares during the period. Torren Management LLC boosted its holdings in Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company's stock valued at $37,000 after acquiring an additional 25 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at about $42,000. Foresight Capital Management Advisors Inc. purchased a new stake in Eli Lilly and Company during the third quarter valued at about $49,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at about $64,000. Institutional investors and hedge funds own 82.53% of the company's stock.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.
The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
